COMPARATIVE EVALUATION OF THE ANTIHYPERTENSIVE EFFECT OF PERINDOPRIL AND LOSARTAN POTASSIUM IN PATIENTS WITH ARTERIAL HYPERTENSION AND STENOTIC CORONARY ATHEROSCLEROSIS BEFORE REVASCULARIZATION: AN OPEN RANDOMIZED COMPARATIVE STUDY
https://doi.org/10.20996/1819-6446-2011-7-3-300-305
Abstract
Aim. To compare effects of perindopril and losartan potassium on the parameters of the ambulatory blood pressure (BP) monitoring (ABPM) and circadian BP profile in patients with arterial hypertension (HT) and stenotic coronary atherosclerosis before myocardium revascularization. Material and methods. 59 patients with HT degree 2-3 at the age of 35-69 were examined. ABPM was performed in all patients. Daily profile was assessed by the degree of nocturnal BP reduction. Patients were randomized to receive perindopril or losartan potassium. Perindopril was administered at dose of 4 mg/day with subsequent rising up to 8 mg/day in next 7 days. The initial dose of losartan potassium was 25 mg with subsequent rising up to 50 mg 2 times a day. Duration of observation was 8 weeks. Results. Perindopril reduced 24-hour and daytime systolic BP (SBP) by 17.2% (p<0.0001), nighttime SBP - by 22.5% (p<0.0001), 24-hour and daytime diastolic BP (DBP) - by 18.3% and 17.6% (p<0.0001), respectively , nighttime DBP - by 27.2% (p<0.0001). Losartan potassium reduced 24-hour SBP by 25.7% (p<0.0001), daytime SBP - by 23.6% (p<0.0001), night-time SBP – by 25.5% (p<0.0001), 24-hour DBP - by 27.4%, daytime DBP - by 26.3%, nighttime DBP - by 18.5% (p=0.003). Perindopril decreased in number of non-dippers by 24,3% and night-peakers by 5.4% as well as increased in number of dippers by 27% and over-dippers by 2.7%. A number of patients with SAD profile corresponding to non-dipper type was 45.5% more in losartan taking than this when perindopril receiving (p=0.027). Conclusion. In patients with HT and stenotic coronary atherosclerosis perindopril therapy increases a number of patients with normal BP profile before myocardium revascularization.
About the Authors
O. A. Osipova
Belgorod State University
Russian Federation
Russian Federation
N. N. Kurbakov
Kursk Regional Clinical Hospital
Russian Federation
Russian Federation
A. G. Ovsyannikov
Kursk State Medical University
Russian Federation
Russian Federation
M. A. Vlasenko
Kharkov Medical Academy of Postgraduate Education
Ukraine
Ukraine
References
1. Cohn J.N. Structual basis of heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91: 2504-2507.
2. Zelveian P.A., Oshchepkova E.V., Buniatian M.S. et al. Circadian rhythm of arterial pressure and state of target-organs in patients with mild and moderate hypertension. Ter Arkh 2001;73(2):33-8. Russian (Зелвеян П.А., Ощепкова Е.В.. Буниатян М.С. и др. Суточный ритм артериального давления и состояние органов-мишеней у больных с мягкой и умеренной формами гипертонической болезни. Тер Архив 2001; 2: 33-38).
3. Maslyaeva L.V., Reznik L.A., Koval' S.N. i dr. Osobennosti remodelirovaniya serdtsa i sosudov u bol'nykh gipertonicheskoy bolezn'yu i sakharnym diabetom 2 tipa. Ukrainskiy terapevticheskiy zhurnal 2005; 3: 62-66. Ukrainian (Масляева Л.В., Резник Л.А., Коваль С.Н. и др. Особенности ремоделирования сердца и сосудов у больных гипертонической болезнью и сахарным диабетом 2 типа. Украинский терапевтический журнал 2005; 3: 62-66).
4. Fagard R.H., Celis H. Prognostic significance of various characteristics of out-of-the-office blood pressure. J Hypertens 2004; 22: 1663-1666.
5. Hope study investigators Effects of an angiotensin-converting-enzime inhibitor, on cardiovascular enents in high-risk patients. N Engl J Med 2000;342:145-53.
6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 20002; 288: 2981-97.
7. Dahlof B., Devereux R.B., Kjeldsen S.E.et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
8. Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensin–converting–enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomized trial. Lancet 1999; 353: 611–6.
9. Bak J.F., Gerdes L.U., Sorensen N.S. et al. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non–insulin–dependent diabetic patients. Am J Med 1992; 92(suppl 4B): 69–72.
10. Santoro D., Natali A., Oalombo C. et al. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 1992. 20:181–91.
11. Pitt B., Pepine C., o’Neill B. et al. Modulation of ACE inhibitor efficacy on coronary endothelial dysfunction by low density lipoprotein cholesterol. J Am Coll Cardiol 1997; 29 (2 suppl A): 70A.
12. Alhenc–Gelas F., Tsai S.J., Callahan K.S. et al. Stimulation of prostaglandin formation by vasoactive mediators in cultured human endothelial cells. Basic Res Cardiol 1982; 24: 723–42.
13. Anderson T.J., Overhiser R.W., Haber H., Charbonneau F. A comparative study of four anti– hypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol 1998; 31 (2 suppl A):32–7A.
14. Mancini G., Henry G., Mancaya C. et al. Angiotensin–converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary disease. The TREND (Trial on reversing Endothelial Dysfunction) study. Circulation 1996;94: 258–65.
15. MacMahon S., Peto R., Cutler J. et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74.
16. Gardner T.J., Horneffer P.J., Manolino T.A. et al. Stroke following coronary artery bypass grafting: a ten-year stady. Ann Thorac surg 1985; 40:574-581.
17. Frye R.L., Kronmal R., Schaff H.V., Myers W.O. for the participants in the Coronary Artery Surgery Study. Stroke in coronary artery bypass graft surgery: an analysis of the CASS experience. Int J Cardiol 1992;36:213-221.
18. Dzyak G.V., Kolesnik T.V., Pogoretskiy Yu.N. Ambulatory blood pressure monitoring. Dnepropetrovsk: Ferz'; 2005. Russian (Дзяк Г.В., Колесник Т.В., Погорецкий Ю.Н. Суточное мониторирование артериального давления. Днепропетровск: Ферзь; 2005).
19. Okhuro T., Imai Y., Tsuji I. et al. Noctural decline in blood pressure, in combination with 24-h pressure, better predicts future death: The Ohasama study. J Hypertens 1998; 16 (Suppl 2): S35.
20. Dudarev M.V., Odintsova N.F., Vasilyev M.Y., Nikolaeva A.V. Clinical efficacy of Perindopril arginine in hypertensive patients with left ventricular hypertrophy. Arterialnaya gipertenziya 2010; 16(6): 542-548. Russian (Дударев М.В., Одинцова Н.Ф., Васильев М.Ю., Николаева А.В. Клиническая эффективность периндоприла аргинина (Престариум А) у пациентов с артериальной гипертонией и гипертрофией левого желудочка. Артериальная гипертензия 2010; 16(6): 542-548).
Review
For citations:
Osipova O.A., Kurbakov N.N., Ovsyannikov A.G., Vlasenko M.A. COMPARATIVE EVALUATION OF THE ANTIHYPERTENSIVE EFFECT OF PERINDOPRIL AND LOSARTAN POTASSIUM IN PATIENTS WITH ARTERIAL HYPERTENSION AND STENOTIC CORONARY ATHEROSCLEROSIS BEFORE REVASCULARIZATION: AN OPEN RANDOMIZED COMPARATIVE STUDY. Rational Pharmacotherapy in Cardiology. 2011;7(3):300-305. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-3-300-305
Views: 1578
Email this article 